πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 2,465 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12201604

Treatment of circadian rhythm disorders

VANDA PHARMACEUTICALS INC. Β· Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12201673

Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusi

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12201601

Treatment for obesity

AXSOME MALTA LTD. Β· Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12201700

Micro- and nano-device for cartilage injury detection and treatment

The Board of Regents of the University of Texas System Β· Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12201617

HDAC6 inhibitors for treatment of metabolic disease and HFpEF

Tenaya Therapeutics, Inc. Β· Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12202880

HLA engineering methods and compositions for treatment of autoimmunity

The Regents of the University of Colorado Β· Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12194078

Methods and compositions related to combined treatment with anti-inflammatories and synthe

Cartesian Therapeutics, Inc. Β· Granted Tue Jan 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12194082

Compositions and methods for treatment of homocystinuria

The Regents of the University of Colorado, a Body Corporate Β· Granted Tue Jan 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12194079

Therapeutic regimen for the treatment of Fabry using stabilized alpha-galactosidase

Protalix Ltd. Β· Granted Tue Jan 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12195804

Treatment of squamous cell carcinoma

The Board of Regents of the University of Texas System Β· Granted Tue Jan 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12195447

Azolopyrimidine for the treatment of cancer-related disorders

Arcus Biosciences, Inc. Β· Granted Tue Jan 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12186368

Compositions and methods for treatment of protease mediated disease

The Regents of the University of California Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12186349

Compositions and methods for C. difficile treatment

Regents of the University of Minnesota Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12186406

Materials and methods for treatment of hereditary haemochromatosis

CRISPR THERAPEUTICS AG Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12186282

Treatment of 22Q11.2 deletion syndrome with cannabidiol

Harmony Biosciences Management, Inc. Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12186314

Compositions and methods for treatment, amelioration, and prevention of anesthesia-induced

Arizona Board of Regents on Behalf of the University of Arizona Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12186285

Compositions and methods of treatment for tinea pedis

Compass Therapeutics LLC Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12186306

Methods of treatment for cystic fibrosis

Vertex Pharmaceuticals Incorporated Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12178848

Methods and compositions for the treatment of exocrine pancreatic insufficiency

The Board of Regents of the University of Texas System Β· Granted Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12180471

Antisense oligonucleotides for the treatment of Stargardt disease

ProQR Therapeutics II B.V. Β· Granted Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12171786

Use of mesenchymal stem cells for the treatment of inflammation

The Regents of the University of California Β· Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12173058

Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta

Mereo Biopharma 3 Limited Β· Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12172969

Deuterated secnidazole for use in the treatment of bacterial vaginosis and methods and use

EVOFEM BIOSCIENCES, INC. Β· Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12171765

Combination therapies using PRMT5 inhibitors for the treatment of cancer

Mirati Therapeutics, Inc. Β· Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted